key: cord-0994770-mc7kgftk
authors: Barnes, K.; Colagiuri, B.
title: Positive attribute framing increases COVID-19 booster vaccine intention for unfamiliar vaccines
date: 2022-01-28
journal: nan
DOI: 10.1101/2022.01.25.22269855
sha: e1d1cc5bba94885bba2d4775112272f3e06fbea6
doc_id: 994770
cord_uid: mc7kgftk

Positive framing has been proposed as a potential intervention to increase COVID-19 vaccination intentions. However, most available research has examined fictitious or unfamiliar treatments. This pre-registered study compared positively and negatively attribute-framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer, Moderna) and measured intentions pre- and post-intervention in 1,222 UK-based participants. Positive framing increased booster intentions among those with low baseline intentions overall. As hypothesized, however, vaccine familiarity significantly modulated this effect, with positive framing being effective for the least familiar vaccine (i.e., Moderna), while standard negative framing appeared to increase intentions for familiar vaccines (AstraZeneca/Pfizer). These findings provide important new evidence that positive framing could improve vaccine uptake globally when switches or new developments require individuals to receive less familiar vaccines - as is currently the case for millions of booster vaccines across the world. Positive framing of familiar vaccines, however, should be treated with caution.

With vaccine efficacy for Severe Acute Respiratory Syndrome Coronavirus 2 38 (COVID-19) waning over time 1,2 and reduced for emerging variants 3,4 , many countries are 39 currently accelerating their COVID-19 booster programmes 5,6 to protect against COVID-19 40 viruses 7,8 . However, vaccine availability does not necessarily translate to vaccine 41 acceptance 9 , with the World Health Organization (WHO) recognising vaccine hesitancy as a 42 global health threat 10 . Side effect apprehension is a primary factor driving this hesitancy 11 , 43 with one study finding 90% of COVID-19 vaccine refusers feared side effects more than the 44 virus itself 12 . Given the recency of booster programmes, evidence for hesitancy among those 45 already vaccinated is sparse. However, side effect severity associated with previous vaccine 46 doses has already been associated with booster hesitancy in one study 13 . Reducing 47 perceptions of negative side effects could be vital for increasing booster acceptance and 48 thereby reducing the global burden of the current COVID-19 pandemic. 49 50 One method of reducing negative perceptions regarding side effects, suggested by the 51 WHO 14 , concerns "message framing" of vaccine-relevant information 15 . Positive attribute 52 framing, where side effect information is framed in terms of the inverse incidence rate (e.g., 53 "60% will not get a sore arm") as opposed to typical negative framing with the standard 54 incidence rate (e.g., "40% will get a sore arm") could be particularly useful for combatting 55 COVID-19 vaccine hesitancy. First, it is directly applicable to side effects. Second, informed 56 consent is maintained as a consequence of statistical consistency across frames 16 . Third, there 57 is preliminary evidence that positive attribute framing can improve vaccination attitudes in 58 other settings. For example, one study on the influenza vaccine found positive attribute 59 framing (hereafter positive framing) reduced the expectation and experience of side effects, 60 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. minutes, all participants provided post-manipulation ratings for the primary and secondary 143 outcomes (as above). Participants were then presented with 14 side effects from the PIL they 144 had read and were required to: 1) assign each to a verbal prevalence category (i.e., very 145 common, common, uncommon, rare, very rare); 2) estimate frequency of occurrence (number 146 of people in 100,000 expected to experience the side effect. 147 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269855 doi: medRxiv preprint 

To determine whether side effect familiarity corresponded with the predetermined 176 factorial categories of Familiarity (i.e., Unfamiliar, Familiar, Same), a within-subjects one-way 177 ANOVA (with Greenhouse-Geisser correction) was run on side effect familiarity ratings 178 collected for the three vaccine types prior to the experimental manipulation. Baseline*Framing*Contrast2: F(1, 1210)=11.19, p=.0008, ηp 2 =.009). Data presented in Figure  220 4b, that depicts this interaction, provides a more nuanced understanding of results. Viewing side 221 effect information of any type appeared to increase average Booster Intention (i.e., post-222 manipulation model estimated means were above zero, for all levels of the baseline covariate 

At pre-and post-manipulation, participants were asked to imagine that the framed 301 vaccine was their only option for a booster and to rate their Satisfaction, Happiness and Anxiety 302 regarding this outcome. In order to reduce the data for analysis, the three variables were entered 303 into a principal components analysis. Component loading suggested that Satisfaction and 304

Happiness loaded onto a similar latent construct, while Anxiety was associated with another. 305 Therefore, Satisfaction and Happiness were averaged together for the subsequent analyses, while 306

Anxiety was treated separately. Two ANCOVAs were run on these outcomes. Message framing has been suggested as a potential intervention to increase COVID-19 377 vaccine uptake 14 . In the present study, positive and negative attribute framing was applied to 378 genuine side effect information from manufacturer PILs for three COVID-19 vaccines 379 (AstraZeneca, Pfizer, Moderna). Booster intention was measured pre-and post-manipulation. 380

Primary analysis revealed that positive framing successfully increased the intention to be 381 vaccinated for unfamiliar vaccines (i.e., Moderna), but appeared to reduce booster intention for 382 the vaccine that had previously been received, as well as for a switch to the Pfizer vaccine among 383 those previously receiving AstraZeneca. In all cases, effects were strongest when baseline 384 booster intentions were low. Increasing booster acceptance among those with low intentions is of 385 substantial importance in protecting against infection from, and transmission of, COVID-19 386 viruses. Our data suggest that any intervention that intends to employ attribute framing should be 387 (i.e., for real vaccines, at high levels of public involvement), the benefit of positive attribute 401 framing was found to wane, or in some instances to be reversed, as familiarity and prior 402 experience with the framed vaccine increased. As such, calls for all PILs to employ positive 403 framing as standard (e.g., 32,46 ) appear premature. Positive framing appears beneficial only for 404 unfamiliar vaccines whereas negative framing, the standard form for communicating side effect 405 information within the European Union, appears beneficial when treatments are well known. 406

The reduced efficacy of positive framing observed as vaccine familiarity increased could 408 be explained by a current theory of attribute framing that posits an interaction between 409 familiarity (a specific manifestation of psychological distance) and the valence of the message 410 surrounding a given attribute or event (e.g., the experience of vaccine side effects). At closer 411 psychological distances (e.g., for vaccines that are more familiar and more likely to be received), 412 negatively framed information has been shown to be more persuasive 47 Estimates of side effect prevalence were found to be quite poor (<~35% accuracy) after 440 reading the information contained in the PILs, irrespective of frame. This is consistent with 441 previous research 39,50-53 and highlights limitations with the current format of communicating side 442 effect information. It was interesting to note that an additional reduction in accuracy was also 443 observed for the positive frame, which did not interact with familiarity. However, patterns within 444 the data were inconsistent, with reduced accuracy associated with the Unfamiliar vaccine 445 appearing exacerbated for verbal prevalence categories but ameliorated for frequency estimates. 446

As such, it is unclear whether positive framing has the potential to undermine informed consent 16 447 by reducing accuracy concerning side effect prevalence. Further, because the present study 448 employed genuine PILs, the side effects participants were required to judge differed across 449 vaccine types. As such, the study was designed only to test for general inaccuracies in side effect In summary, the present study demonstrates that the ability of positive framing to 474 successfully increase booster intention for genuine COVID-19 vaccines is critically moderated 475 by the familiarity of that vaccine. Positive framing can improve vaccine intention for unfamiliar 476 vaccines, but may actually decrease intentions for familiar vaccines. The data therefore provide 477 novel insights into the benefits of positive framing for COVID-19 vaccines and beyond. As such, 478

we recommend that if positive attribute framing is to be employed, close attention must be paid 479 to the type of treatment being framed as well as the likely recipients of the framed information. 480 Importantly, in the context of the current COVID-19 pandemic, positive framing appears capable 481 of improving uptake of COVID-19 vaccines when switches or new developments require 482 individuals to receive unfamiliar vaccines, as is the case for many booster vaccine programmes 483 globally, but should be treated with caution for familiar vaccines. Cross-sectional data were collected online via Qualtrics, with the survey accessible to 505 personal computer, tablet, and smartphone. The 'force response' option was used to ensure 506 complete cases for all outcome variables. Participants completed the survey in one sitting and 507

were not able to return to the study URL. After pre-screening, those meeting the inclusion 508 criteria were provided with a participant information statement detailing the aims of the study 509 and gave their digital informed consent. Those not meeting these criteria were directed away 510 from the survey. 511

Participants completed demographic items and identified which COVID-19 vaccine they 512 had previously received (AstraZeneca or Pfizer). Stratified randomisation to the six experimental 513 groups occurred at this point using the inbuilt Qualtrics randomisation function. Quotas were set 514 to limit data collection to 600 participants from each vaccine type (AstraZeneca/Pfizer), with 100 515 from each group randomised to the six experimental conditions. Because Qualtrics tallies quotas 516 on survey completion but does not account for participants currently in the experimental 517 pipeline, the final sample contained 22 more participants than projected. Statistical analysis did 518 not take place until after exclusions had been made and all quotas were closed. 519 520 After randomisation, participants responded to items concerning the number of months 521 since their last COVID-19 vaccine and familiarity with side effects of the three framed vaccines. 522

For each vaccine type, participants then rated their booster intention, perceived booster side 523 effect severity, perceived booster risk, and booster acceptance (satisfaction, happiness, and 524 anxiety). Responses made to the vaccine type that matched with the experimental condition to 525 which the participant had been assigned were employed as baseline measures. Responses to all 526 other vaccine types were recorded for use in a concurrent, but separate, pre-registered study 527 (#78370; aspredicted.org/8e6af.pdf). PILs containing the positively or negatively framed side 528 effect information were then displayed for two minutes, using a timer embedded in the survey. 529

Participants could not proceed until this time had elapsed. Post-manipulation booster intention, 530 perceived booster side effect severity, perceived booster risk, and booster acceptance were then 531 recorded. Finally, fourteen side effects described in the PILs were presented, with participants 532 required to assign each to a verbal prevalence descriptor (very common, common, uncommon, 533 rare, very rare) and estimate how many people (out of 100,000) taking the vaccine would 534 'extremely'). Satisfaction, happiness, and anxiety were rated as sub-items, each yielding a score 583 of 0 -100. Where the vaccine type was the same as that previously received by the participant, 584 wording was changed from 'switching to' to 'continuing with'. Wording of 1 -3 was adapted 585 from previous research 39 . 586

Genuine PILs for the AstraZeneca, Pfizer, and Moderna vaccine were abridged to include 589 the manufacturer's description of each vaccine, what it is used for, and critically, the possible 590 side effects resulting from administration. Side effects were retained in their original form and 591 order. For both the negatively and positively framed PILs, verbal descriptors were in keeping 592 with those published by the manufacturer (i.e., very common, common, uncommon, rare, very 593 rare, not known). Wording of assigned frequency bands employed in the negatively framed PILs 594 was also identical to that of the manufacturer. However, this was inverted in the positively 595 framed PILs to stress the number of individuals not affected (e.g., "Common (90 in 100 or more 596 people may not be affected)"). As multi-modal forms of side effect presentation (e.g., written, 597 pictorial, verbal) may elicit larger framing effects 16 , and numeracy is less likely to moderate the 598 effect of attribute framing for graphical presentations 59 , positive PILs additionally included a 599 graphical representation of side effect risk to enhance the manipulation. For an example of the 600 wording used to frame side effects see Figure 2 . 601 602

Participants responded to the four vaccine perception items listed above under Baseline 604

Measures (booster intention, booster side effect severity, booster risk, booster acceptance), but 605 only in relation to the vaccine type outlined in the PIL to which they were assigned. 606 607

To determine whether positive framing augments the perception of side effect occurrence 609 relative to true prevalence rates, fourteen side effects were presented from each PIL. Eleven of 610 these were associated with concrete prevalence brackets in the original PILs, while the remaining 611 three were assigned to the 'unknown' category (i.e., could not be estimated at the time of PIL 612 publication). For each side effect, participants were required to identify the correct verbal 613 descriptor (very common, common, uncommon, rare, very rare): "based on the information that 614 with Type III Sum of Squares. An alpha of .05 was accepted as the threshold for statistical 624 significance. Sample size (estimated N=1200) was calculated based on an a priori power analysis 625 (95% power, alpha=.05, effect size f 2 =0.02) for a separate study run concurrently that contained 626 more predictor variables (N=9), and therefore required more power, than the study presented 627 here (further details are contained in the study pre-registration form). An effect size for attribute 628 framing was additionally derived from previous research (average effect size r= 0.175) 16 . An a 629 priori power analysis based on this effect size required a total of 491 participants, providing 630 reassurance that the projected sample size for the study above provided ample power to detect an 631 effect of framing in the present study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 28, 2022. 

Vaccine effectiveness and duration of protection of Comirnaty

Vaxzevria and Spikevax against mild and severe COVID-19 in the UK

Waning immunity of the BNT162b2 vaccine: A nationwide study 653 from Israel

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer 656

BNT162b2 elicited neutralization and requires ACE2 for infection

Improved neutralization of the SARS-CoV-2 Omicron variant after 659

BNT162b2 COVID-19 vaccine boosting

Covid-19 booster vaccines: What we know and who's doing what

All adults to be offered COVID-19 boosters by end of

Third doses of COVID-19 vaccines reduce infection 667 and transmission of SARS-CoV-2 and could prevent future surges in some populations: a 668 modeling study

Serological responses to COVID-19 booster vaccine in England

Vaccine hesitancy: Definition, scope and determinants

Ten threats to global health in 2019 (World Health Organisation

COVID-19 vaccine acceptance and hesitancy in low-and middle-677 income countries

Why won't Americans get vaccinated? (Economist/YouGov poll

Willingness to Receive the Booster

Data for action: achieving high uptake of COVID-19 684 vaccines: gathering and using data on the behavioural and social drivers of vaccination: 685 a guidebook for immunization programmes and implementing partners: interim 686 guidance

All Frames Are Not Created Equal: A 689

Typology and Critical Analysis of Framing Effects

Decision Processes

Can Positive Framing Reduce Nocebo Side Effects? Current Evidence 692 and Recommendation for Future Research

Framing effects on expectations

decisions, and side effects experienced: The case of influenza immunization

Effective or ineffective: Attribute framing 697 and the human papillomavirus (HPV) vaccine

Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the 701

United States and the United Kingdom: A Randomized Controlled Trial

Do Messages Matter? Investigating the Combined 704 Effects of Framing, Outcome Uncertainty, and Number Format on COVID-19

Vaccination Attitudes and Intention

Promoting COVID-19 Vaccination: The Interplay of Message 707

Psychological Uncertainty, and Public Agency as a Message Source

A retrospective analysis of social media posts pertaining to COVID-710 19 vaccination side effects

Vaccine-related advertising in the Facebook Ad Archive

COVID-19 vaccines

Positive versus Negative Framing of a Hypothetical Infant 716

Immunization: The Influence of Involvement

Climate Change Versus Global Warming: Who 719

Is Susceptible to the Framing of Climate Change?

Effect of combining attribute and goal framing within 722 messages to change vaccination behavior

SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine 726

Composition (TAG-CO-VAC) (World Health Organization

Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by 731 spring

Patients' beliefs and behaviours are 734 associated with perceptions of safety and concerns in a hypothetical biosimilar switch

What happens to patients who have their asthma device switched without 737 their consent?

The Effect of Positively Framing Side-Effect Risk in Two 739

Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A 740

Randomised Trial of 16-to 75-Year-Olds in England

Attribute Framing and Goal Framing Effects in 742

Information framing effects in social and 745 personal decisions

Framing of outcome and probability of 747 recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in 748 hypothetical patient scenarios

Framing of information: Its influence upon decisions of doctors and 750 patients

Predicting Expectations of Side-Effects for Those Which 752

Are Warned Versus Not Warned About in Patient Information Leaflets

Patient information 755 leaflets: informing or frightening? A focus group study exploring patients' emotional 756 reactions and subsequent behavior towards package leaflets of commonly prescribed 757 medications in family practices

Communicating risk of medication side effects

An empirical evaluation of EU recommended terminology

Research and analysis: Coronavirus vaccine -weekly summary of Yellow Card reporting 762 (gov.uk

Research design and statistical analysis

ANOVA for the behavioural sciences researcher

Making and Trial-entry Preferences: The Effects of "Framing" Information about Short-770 term Toxicity and Long-term Survival

Message framing with respect to decisions about 772 vaccination: The roles of frame valence, frame method and perceived risk

Effects of framing on 775 teratogenic risk perception in pregnant women

Explaining all without causing unnecessary 777 harm: Is there scope for positively framing medical risk information? Patient Education 778 and Counseling

When not to accentuate the positive: Re-780 examining valence effects in attribute framing

Decision Processes

Fighting the Infodemic on Two Fronts: Reducing False Beliefs 783

Without Increasing Polarization

Does correcting myths about the flu vaccine work? An 785 experimental evaluation of the effects of corrective information

People's Understanding of Verbal Risk 788

Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18-to 789 65-Year-Olds in England

Is 15 per cent very common? Informing people 791 about the risks of medication side effects

Associated with Medication Use

Communicating the Risk of Side Effects to Patients

Predicting Human Papillomavirus Vaccine Uptake in 798

Young Adult Women: Comparing the Health Belief Model and Theory of Planned 799

The intention to get 801 vaccinated against influenza and actual vaccination uptake of Dutch healthcare personnel

Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual 805 Vaccination Behavior? Women's Health Issues

Video-based messages to reduce COVID-19 vaccine 807 hesitancy and nudge uptake

Intention-Behavior Relations: A Conceptual and Empirical Review

Are highly numerate individuals invulnerable to attribute 811 framing bias? Comparing numerically and graphically represented attribute framing

Uncommon (may affect up to 1 in 100 people) Uncommon (990 in 1,000 or more people may not be affected)